Effects of vitamin D and calcium supplementation on bone mineral density among Thai youth using daily HIV pre-exposure prophylaxis.

Plain-language guide to PMID 33040465 (2020): open-label randomized controlled trial of Vitamin D, K2, Magnesium and Zinc.

Key Facts

PMID: 33040465
Journal: Journal of the International AIDS Society
Year: 2020
Study type: Randomized Controlled Trial
Authors: Pornpaisalsakul K et al. (8 authors)
DOI: 10.1002/jia2.25624

What This Study Did, in Plain Language

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

Tenofovir disoproxil fumarate with emtricitabine (TDF/FTC) is used for HIV pre-exposure prophylaxis (PrEP).

TDF may affect bone mineral density (BMD), particularly in youth who are at a stage of peak bone mass accrual.

Who Took Part

By PubMed's age tags, the people studied were teenagers and young adults, men only.

How the Study Was Run

In design terms this was a randomized and open-label study.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Everyone knew when Vitamin D, K2, Magnesium and Zinc was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

This open-label randomized trial was conducted in male youth aged between 15 and 24 years.

PrEP users were defined as taking at least two tablets/week (tenofovir-diphosphate level of >350 fmol/punch).

Lumbar spine (L2-L4) BMD (LSBMD) was evaluated by dual-energy X-ray absorptiometry scan zero and six months after PrEP initiation.

What Was Measured

Topics PubMed links to this paper include Absorptiometry, Photon, Anti-HIV Agents, Bone Density, Calcium, Dietary Supplements, Emtricitabine and HIV Infections.

The authors tagged it with the keywords HIV pre-exposure prophylaxis, bone mineral density, vitamin D, young men who have sex with men and young transgender women.

What This Means in Plain Language

The paper is a randomized and open-label study of Vitamin D, K2, Magnesium and Zinc.

Results are reported in around 11 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2020 (Journal of the International AIDS Society), a journal based in Switzerland.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.

Our Notes on the Compound

Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.

Vitamin D, K2, Magnesium and Zinc in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.